Paratiroid ve Akciğer
Özet
Paratiroid bezinden salgılanan parathormon (PTH) ile benzer dizi homolojisine sahip olan parathormon ilişkili protein (PTHrP), akciğerin fetal gelişiminden erişkin dönemdeki hasar tamirine ve kanser patogenezine kadar geniş bir yelpazede kritik roller oynamaktadır. Fetal dönemde akciğer morfolojisi ve sürfaktan sentezi için gerekli olan PTHrP, erişkinlerde ise özellikle tip 2 alveolar hücreler tarafından üretilerek doku onarımını desteklemektedir. Akciğer kanserlerinin büyük bir bölümünde tümör hücreleri tarafından yüksek oranda eksprese edilen bu protein, tanısal süreçlerde potansiyel bir biyobelirteç niteliği taşımaktadır. Bununla birlikte malignite seyrinde uygunsuz salınımı, nükleer faktör-κ ligand reseptör aktivatörü (RANKL) üzerinden kemik yıkımını tetikleyerek maligniteye bağlı humoral hiperkalsemi (HOM) tablosuna yol açmaktadır. Klinik olarak halsizlikten aritmi ve komaya kadar değişen semptomlarla seyreden bu endokrin paraneoplastik sendromun tanısında düsük serum fosforu ile baskılanmış/normal PTH düzeyleri ayırt edicidir. Tedavi yönetiminde ise serum kalsiyum seviyesini düsürmek ve altta yatan maligniteyi kontrol altına almak amacıyla agresif salin hidrasyonu, osteoklast aktivitesini önleyen bisfosfonatlar (özellikle zoledronat) ile dirençli olgularda kalsitonin ve loop diüretikleri kullanılmaktadır.
Parathyroid hormone-related protein (PTHrP), sharing sequence homology with parathyroid hormone (PTH) secreted from parathyroid glands, plays critical roles ranging from fetal lung development to adult tissue repair and lung cancer pathogenesis. Essential for fetal lung morphology and surfactant phospholipid synthesis, PTHrP is primarily produced by alveolar type 2 cells in adults to mediate alveolar epithelial recovery following lung injuries. High expression levels of PTHrP by tumor cells in a significant majority of lung cancers highlight its potential clinical utility as a diagnostic biomarker. However, its inappropriate secretion in malignancies stimulates bone resorption via receptor activator of nuclear factor-κ ligand (RANKL) expression, resulting in humoral hypercalcemia of malignancy (HCM). This paraneoplastic syndrome presents with diverse clinical symptoms ranging from fatigue to life-threatening arrhythmias and coma, and its differential diagnosis relies on demonstrating suppressed/normal PTH levels alongside low serum phosphorus. Therapeutic management aims to normalize calcium levels and treat the underlying tumor, utilizing aggressive saline hydration, osteoclast-inhibiting bisphosphonates (particularly zoledronate), and calcitonin or loop diuretics in refractory cases.
Referanslar
Hastings, R. H. (2004). Parathyroid hormone-related protein and lung biology. Respiratory physiology & neurobiology, 142(2-3), 95-113.
Moniz, C., Burton, P. B. J., Malik, A. N., Dixit, M., Banga, J. P., Nicolaides, K., ... & McGregor, A. M. (1990). Parathyroid hormone-related peptide in normal human fetal development. Journal of molecular endocrinology, 5(3), 259-266.
Rubin, L. P., Kifor, O., Hua, J., Brown, E. M., & Torday, J. S. (1994). Parathyroid hormone (PTH) and PTH-related protein stimulate surfactant phospholipid synthesis in rat fetal lung, apparently by a mesenchymal-epithelial mechanism. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1223(1), 91-100.
Hastings, R. H., Quintana, R. A., Sandoval, R., Burton, D. W., & Deftos, L. J. (2003). Amino-terminal and midmolecule parathyroid hormone-related protein, phosphatidylcholine, and type II cell proliferation in silica-injured lung. American Journal of Physiology-Lung Cellular and Molecular Physiology, 285(6), L1312-L1322.
Hastings, R. H., Araiza, F., Burton, D. W., & Deftos, L. J. (2004). Role of parathyroid hormone-related protein in lung cancer cell survival. Chest, 125(5), 150S.
Adamson, I. Y. (1974). The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen. Lab Invest, 30, 35-42.
Brandt, D.W., Burton, D.W., Gazdar, A.F., Oie, H.E., Deftos, L.J., 1991. All major lung cancer cell types produce parathyroid hormone-like protein: heterogeneity assessed by high performance liquid chromatography. Endocrinology 129, 2466
Nishigaki, Y., Ohsaki, Y., Toyoshima, E., & Kikuchi, K. (1999). Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients. Clinical cancer research, 5(6), 1473-1481.
Truong, N. U., Edwardes, M. D. D., Papavasiliou, V., Goltzman, D., & Kremer, R. (2003). Parathyroid hormone–related peptide and survival of patients with cancer and hypercalcemia. The American journal of medicine, 115(2), 115-121.
Thomas, L., Kwok, Y., & Edelman, M. J. (2004). Management of paraneoplastic syndromes in lung cancer. Current treatment options in oncology, 5(1), 51-62.
Rankin, W., Grill, V., & Martin, T. J. (1997). Parathyroid hormone‐related protein and hypercalcemia. Cancer: Interdisciplinary International Journal of the American Cancer Society, 80(S8), 1564-1571.
Rosol, T. J., & Capen, C. C. (1992). Mechanisms of cancer-induced hypercalcemia. Laboratory investigation; a journal of technical methods and pathology, 67(6), 680-702.
Akyay, Ö. Z., Selek, A., & Tarkun, İ. (2015). AKCİĞER KANSERİ, ENDOKRİNOPATİLER VE PARANEOPLASTİK SENDROMLAR. Bulletin of Thoracic Surgery/Toraks Cerrahisi Bülteni, 9(4).
Ralston, S. H., Coleman, R., Fraser, W. D., Gallagher, S. J., Hosking, D. J., Iqbal, J. S., ... & Sampson, D. (2004). Medical management of hypercalcemia. Calcified tissue international, 74(1), 1-11.
Hu, M. I. N., Glezerman, I., Leboulleux, S., Insogna, K. L., Gucalp, R. A., Misiorowski, W., ... & Jain, R. K. (2013). Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).
Ross, J. R., Saunders, Y., Edmonds, P. M., Patel, S., Broadley, K. E., & Johnston, S. R. D. (2003). Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. Bmj, 327(7413), 469.
